Paula Bergengruen
Papers
1
Total Citations
12
H-Index
1
About
Paula Bergengruen is a leading figure in the emerging field of cardiac radioablation, where she bridges radiation oncology and cardiology to treat life-threatening arrhythmias. Her most impactful work centers on the RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial, a landmark multicenter initiative. As the lead author of the 2022 benchmarking study, she established critical treatment planning standards across multiple platforms, ensuring reproducibility and safety in this high-stakes procedure. Her contributions have been recognized with 12 citations for this foundational paper, which serves as a technical roadmap for clinics worldwide adopting this non-invasive therapy. Bergengruen’s research directly addresses the challenge of targeting moving cardiac tumors while sparing healthy tissue, combining advanced imaging with precision dosimetry. Her work not only advances clinical protocols but also fosters interdisciplinary collaboration, making her a key architect in translating stereotactic body radiotherapy from oncology to cardiology. For students and researchers, her studies exemplify how rigorous multi-institutional validation can transform experimental treatments into standard-of-care options for patients with refractory ventricular tachycardia.
Research Focus
Key Achievements
Top Papers
- 1